000			02062nam a22003734a 4500
001			ebr10275622
003			CaPaEBR
006			m u
007			cr cn|||||||||
008			080527s2009 njua sb 001 0 eng
010			_z 2008022807
016	7		_z101474921 _2DNLM
020			_z0470229640 (cloth)
020			_z9780470229644 (cloth)
040			_aCaPaEBR _cCaPaEBR
035			_a(OCoLC)317483524
050	1	4	_aRC677 _b.T87 2009eb
082	0	4	_a616.1/23061 _222
100	1		_aTurner, J. Rick.
245	1	0	_aIntegrated cardiac safety _h[electronic resource] : _bassessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance / _cJ. Rick Turner, Todd A. Durham.
260			_aHoboken, N.J. : _bJohn Wiley & Sons, _cc2009.
300			_axxviii, 470 p. : _bill.
504			_aIncludes bibliographical references (p. 397-455) and index.
505	0		_aThe importance of cardiac safety assessments -- The biological basis of adverse drug reactions -- Cardiac structure and function -- Cardiac pathophysiology and disease -- Drug discovery and drug design -- Nonclinical development -- The thorough QT/QTc trial -- General safety assessments -- Therapeutic use trials and meta-analyses -- Assessment methodologies in nonexperimental postmarketing surveillance -- Postmarketing proarrhythmic cardiac safety assessments -- Generalized cardiac safety -- Medication errors, adherence, and concordance -- Future directions in drug safety.
533			_aElectronic reproduction. _bPalo Alto, Calif. : _cebrary, _d2013. _nAvailable via World Wide Web. _nAccess may be limited to ebrary affiliated libraries.
650		0	_aCardiovascular toxicology.
650		0	_aHeart _xEffect of drugs on.
650		0	_aDrugs _xSide effects _xTesting.
650		0	_aDrugs _xSafety measures.
655		7	_aElectronic books. _2local
700	1		_aDurham, Todd A.
710	2		_aebrary, Inc.
856	4	0	_uhttp://site.ebrary.com/lib/rucke/Doc?id=10275622 _zAn electronic book accessible through the World Wide Web; click to view
999			_c6001 _d6001